DESCAR-T, National Registry for Patients with Hematological malignancies, Eligible for CAR T-Cell Therapy

DESCAR-T, National Registry for Patients with Hematological malignancies, Eligible for CAR T-Cell Therapy

The DESCAR-T study is a national registry to follow-up patients who have been treated with CAR T-cells. The collected data will allow to better understand the short- and long-term efficacy and safety profile of these new therapies in real-life setting.